ulcerative colitis

PWE-065 Patients’ perception of faecal calprotectin testing in inflammatory bowel disease: results from a prospective patient based survey
R Kalla, B Crooks, V Hall, S Tatersall, Z Ndlovu, A Simon, K Moriarty, G Lipscomb, S Singh

Gut Jul 2017, 66 (Suppl 2) A158-A159; DOI: 10.1136/gutjnl-2017-314472.311
PTH-067 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
BG Feagan, F Bhayat, JM Khalid, W Palo, A Blake, M Shetzline, SP Travis

Gut Jul 2017, 66 (Suppl 2) A239-A240; DOI: 10.1136/gutjnl-2017-314472.466
PTH-071 The changing face of surgery for ulcerative colitis: analysis of 10 years of colectomy data
R Ratnakumaran, N Scott, AC Ford, PJ Hamlin

Gut Jul 2017, 66 (Suppl 2) A241-A242; DOI: 10.1136/gutjnl-2017-314472.470
OC-049 Exaggerated acute inflammation in ulcerative colitis, and promotion of its resolution by 5-aminosalicylates through anti-inflammatory hydroxy fatty acid biosynthesis
DJ Marks, R Wysoczanski, AC Kendall, M Motwani, R Vega, FZ Rahman, S McCartney, SL Bloom, A Nicolaou, DW Gilroy, AW Segal

Gut Jul 2017, 66 (Suppl 2) A25-A26; DOI: 10.1136/gutjnl-2017-314472.49
PTH-099 A novel approach to the implementation of biosimilar infliximab ct-p13 for the treatment of ibd utilising therapeutic drug monitoring: the edinburgh experience
N Plevris, TA Manship, A Deekae, GR Jones, CL Noble, J Satsangi, AG Shand, ID Arnott, CW Lees

Gut Jul 2017, 66 (Suppl 2) A255-A257; DOI: 10.1136/gutjnl-2017-314472.498
PTH-112 Assessing the effect of ethnicity on urinary metabolic profiles in inflammatory bowel disease
LC Hicks, STR Powles, LWL Chong, J Swann, E Holmes, HRT Williams, TR Orchard

Gut Jul 2017, 66 (Suppl 2) A261-A263; DOI: 10.1136/gutjnl-2017-314472.511
PWE-005 New in vitro human faecal fermentation system for diagnosis and treatment of gastrointestinal disorders using continuous intestinal gas profiling
A Rotbart, K Kalantar-zadeh, JZ Ou, CK Yao, JG Muir, PR Gibson

Gut Jul 2017, 66 (Suppl 2) A128; DOI: 10.1136/gutjnl-2017-314472.250
PWE-062 Effectiveness and safety of vedolizumab (vdz) in ibd patients: a multicentre experience of ‘real world data’ from the uk
MV Lenti, S Levison, E Eliadou, R Robert Willert, K Kemp, C Stansfield, A Assadsangabi, S Singh, B Crooks, S Tattersall, C Kenneth, S Subramanian, C Probert, D Storey, B Gregg, P Smith, E Liu, JK Limdi, A Johnston, PJ Hamlin, CP Selinger

Gut Jul 2017, 66 (Suppl 2) A157-A158; DOI: 10.1136/gutjnl-2017-314472.308
OC-047 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character
R Kalla, AT Adams, S Vatn, F Bonfiglio, ER Nimmo, NA Kennedy, N Ventham, MH Vatn, P Ricanek, D Bergemalm, J Halfvarson, JD Soderholm, M Pierik, L Torkvist, F Gomollon, I Gut, J Jahnsen, J Satsangi, IBDCharacter Consortium

Gut Jul 2017, 66 (Suppl 2) A24-A25; DOI: 10.1136/gutjnl-2017-314472.47
PTH-077 Vedolizumab in the real world: a tertiary centre experience
C Manning, S Chan, M Tremelling, R Tighe

Gut Jul 2017, 66 (Suppl 2) A244; DOI: 10.1136/gutjnl-2017-314472.476

Main menu

ulcerative colitis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

ulcerative colitis

Pages